Ruxolitinib cream + Vehicle cream
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cutaneous Lichen Planus
Conditions
Cutaneous Lichen Planus
Trial Timeline
Nov 23, 2022 → Feb 26, 2024
NCT ID
NCT05593432About Ruxolitinib cream + Vehicle cream
Ruxolitinib cream + Vehicle cream is a phase 2 stage product being developed by Incyte for Cutaneous Lichen Planus. The current trial status is completed. This product is registered under clinical trial identifier NCT05593432. Target conditions include Cutaneous Lichen Planus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06804811 | Phase 3 | Recruiting |
| NCT06959225 | Phase 3 | Recruiting |
| NCT06958211 | Phase 3 | Recruiting |
| NCT06548360 | Phase 3 | Recruiting |
| NCT06238817 | Phase 3 | Completed |
| NCT05764161 | Phase 3 | Completed |
| NCT05755438 | Phase 3 | Completed |
| NCT05635838 | Phase 2 | Completed |
| NCT05593432 | Phase 2 | Completed |
| NCT05593445 | Phase 2 | Completed |
| NCT04896385 | Phase 2 | Completed |
| NCT03745638 | Phase 3 | Completed |
| NCT03745651 | Phase 3 | Completed |
| NCT03099304 | Phase 2 | Completed |
Competing Products
20 competing products in Cutaneous Lichen Planus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONTAK (denileukin difitox, DAB389IL-2) | Eisai | Approved | 85 |
| ONTAK | Eisai | Approved | 85 |
| E7777 9 mcg/kg | Eisai | Phase 3 | 77 |
| ONTAK | Eisai | Approved | 85 |
| Mogamulizumab | Kyowa Kirin | Approved | 85 |
| Mogamulizumab + Brentuximab vedotin | Kyowa Kirin | Phase 1 | 33 |
| Mogamulizumab | Kyowa Kirin | Phase 2 | 52 |
| KW-0761 + Vorinostat | Kyowa Kirin | Phase 3 | 77 |
| Enzastaurin | Eli Lilly | Phase 2 | 52 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Comparator: vorinostat | Merck | Pre-clinical | 23 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| TR701 FA | Merck | Phase 2 | 52 |
| MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Tulisokibart + Placebo | Merck | Phase 2 | 52 |
| Aspirin + Ipilimumab + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Mogamulizumab | Merck | Phase 2 | 52 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 77 |